Elixir Associates reposted this
☢️🚀 !Exciting News from Curium Pharma! 🚀☢️ Curium Pharma has submitted its 505(b)(2) New Drug Application for Lu-177 Dotatate Injection to the FDA! This groundbreaking therapy targets somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETS). 🎯 This submission is a major milestone in Curium's journey to revolutionize cancer treatment through advanced nuclear medicine. 💬 Michael Patterson, Curium North America's CEO, stated: "Our application for Lutetium Lu 177 Dotatate Injection marks an important step towards making nuclear medicine-based cancer therapies more accessible and reliable for patients and caregivers." #CuriumPharma #NuclearMedicine #CancerTreatment #FDA #Innovation #Healthcare #PharmaNews #MedicalAdvancement #CancerResearch #PatientCare #RadioligandTherapy #Biotech
